Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lu 02-750 is a dopaminergic agent acting on brain areas affected in Parkinson's disease. In animal models, the compound has demonstrated very convincing effects as compared to conventional treatments. Expectations are that the compound can offer Parkinson's patients a new and higher level of disease control.
"Focus at Lundbeck Research is to discover new innovative treatments that address unmet needs and offer clear benefits to the patients and we believe that Lu 02-750 has the potential to improve the treatment and life quality of patients suffering from Parkinson's disease", says Executive Vice President Peter Høngaard Andersen, Head of Research at Lundbeck and continues: "Lundbeck is actively pursuing external technologies and collaborations and Lu 02-750 has been discovered in close collaboration with Professor Håkan Wikström, Groningen University and Axon Biochemicals B.V."
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.